サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：デジタル吸入器の世界市場 - 2023年～2030年
市場調査レポート
商品コード
1374806

デジタル吸入器の世界市場 - 2023年～2030年

Global Digital Dose Inhalers Market -2023-2030

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
デジタル吸入器の世界市場 - 2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

デジタル吸入器は、電子機器と連動して患者の健康状態を毎日チェックできる呼吸補助具です。これらは、喘息や閉塞性疾患のような呼吸器疾患を持つ人々にとって特に有用です。これらの吸入器のセンサーが、毎日適切な時間に薬を服用するよう使用者に促します。

デジタル吸入器健康システムは、吸入器の作動を監視するために電気機械センサーとマイクロエレクトロニクスを使用します。いくつかのガジェットには、リンクされたスマートフォン、患者と通信するモバイルアプリ、クラウドサーバー、および医師がダッシュボードデータを見るためのポータルが含まれます。

デジタル吸入器の中には、汚染や花粉のレベルを測定したり、患者が忘れた場合にアラームを発するものもあります。スマート吸入器は、患者が服用を忘れたり、何度も服用を繰り返したりしたことを通知し、服用を時間通りに、自動的かつ簡単に行うよう患者に注意を促します。

市場力学：市場促進要因と市場抑制要因

呼吸器疾患の有病率の上昇

呼吸器疾患の増加は、予測期間中に市場が成長するための主要促進要因の1つです。喘息やCOPDのような呼吸器疾患の増加以来、デジタル吸入器デバイスの使用は、多くの場合、実際に市場成長を増加させる急速に使用されています。

例えば、疾病管理予防センターによると、COPDは推定2億人が罹患し、毎年320万人が死亡しており、世界的に死亡原因の第3位となっています。

喘息は最も一般的な非感染性疾患のひとつで、世界で2億6,200万人が罹患しています。2022年には新たに220万人近くが肺がんに罹患し、180万人が死亡すると予想されており、肺がんは世界のがん死亡の4人に1人を占めています。下気道感染症または肺炎は顕著な死因であり、主に中低所得国（LMICs）において毎年240万人以上の死亡者を出しています。COVID-19は世界中で肺炎による死亡者数を大幅に増加させています。

さらに、吸入器の技術的進歩、データ駆動型ヘルスケア、老年人口の有病率の上昇、遠隔医療の上昇などが、予測期間中に市場をさらに牽引するでしょう。

市場力学：抑制要因

多くの抑制要因が予測期間中の市場成長を阻害します。例えば、投薬コストの増加、デバイスに関連する高コスト、プライバシーとデータセキュリティの懸念、規制上のハードル、喘息に利用可能な高度な治療とデバイスに関する人々の認識不足などが挙げられます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 呼吸器疾患の有病率の上昇
      • 技術の進歩
    • 抑制要因
      • セキュリティ問題
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 デバイスタイプ別

  • 定量吸入器
  • ドライパウダー吸入器

第8章 用途別

  • 喘息
  • 慢性閉塞性肺疾患
  • その他

第9章 タイプ別

  • ブランド
  • ジェネリック

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他のアジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Novartis International AG
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Propeller Health
  • H&T Presspart Manufacturing Ltd
  • AptarGroup Inc
  • Amiko Digital Health Limited
  • Trudell Medical UK Limited
  • ReciPharm
  • Sensirion
  • Teva Pharmaceuticals
  • Cohero Health, Inc

第14章 付録

目次
Product Code: MD7244

Overview

Digital dose inhalers are breathing aids that can be linked to electronic devices to check on a patient's health every day. These are especially helpful for people with respiratory diseases like asthma or obstructive diseases. Sensors in these inhalers prompt the user to take medicine at the appropriate times each day.

Digital dose inhaler health systems use electromechanical sensors and microelectronics to monitor inhaler actuation. Some gadgets include a linked smartphone, a mobile app that communicates with the patient, a cloud server, and a portal for the physician to see dashboard data.

Some digital dose inhalers can measure pollution or pollen levels or alarm patients if they forget them. Smart inhalers notify patients of missed or repeated doses and remind them to take their dosages on time, automatically, and easily.

Market Dynamics: Drivers and Restraints

Rise in prevalence of respiratory diseases

The rise in the prevalence of respiratory disease is one of the key drivers that helps the market to grow during the forecast period. Since the rise in respiratory diseases like asthma and COPD the use of digital dose inhaler devices is often used rapidly which indeed will increase the market growth.

For instance, according to the Centers for Disease Control and Prevention COPD affects an estimated 200 million people, with 3.2 million dying each year, making it the third-leading cause of mortality globally.

Asthma is one of the most common noncommunicable illnesses, impacting 262 million people worldwide. With almost 2.2 million new instances of lung cancer expected in 2022 and 1.80 million fatalities, lung cancer accounts for one in every four cancer deaths worldwide. Lower respiratory tract infection or pneumonia is a prominent cause of death, accounting for more than 2.4 million fatalities each year, primarily in low and middle-income countries (LMICs). COVID-19 has significantly increased pneumonia fatalities worldwide.

Furthermore, technological advancements in technological advancements in inhalers, Data-Driven Healthcare, the rise in the prevalence of the geriatric population, and rise in the telemedicine's and others will further drive the market during the forecast period.

Market Dynamics: Restraint

Many restraint factors hampers the market growth during the forecast period some of the mare like, increasing medication cost and high cost associated with devices, privacy and data security concerns, regulatory hurdles, and lack of awareness among people regarding advanced treatment and devices available for asthma are going to impede the market growth.

Segment Analysis

The global digital dose inhalers is segmented based on product type, type, application, type, distribution channel and region.

The metered-dose inhaler from the device type segment accounted for approximately 41.2% of the market share

The metered-dose inhaler from the device type segment accounted for 41.2% and it is expected to be dominated during the forecast period. A metered-dose inhaler has a pressurized canister of medication that fits into a mouthpiece. In most instances, a dose of medication is released into your lungs by pushing the canister into the mouthpiece. Another type releases medication automatically when you inhale. Some metered-dose inhalers have counters that track how many doses remain.

For instance, on July 2023, Hormosan Pharma GmbH (Hormosan), Lupin's wholly-owned subsidiary in Germany, stated that they have been launched Luforbec 100/6 (beclometasone 100µg / for motel 6µg), a fix combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany.

Moreover, on February 8 2022, Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, stated the launch of HeroTracker Sense, a novel digital respiratory health solution that transforms a standard metered dose inhaler (pMDI) into a smart connected healthcare device.

HeroTracker Sense is designed to help improve the lives of patients around the world suffering from chronic respiratory diseases such as asthma, COPD, Cystic Fibrosis and other respiratory conditions caused by COVID-19, to track their usage and facilitate improved adherence to their prescribed therapy.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to rigorous research and development activities and increased awareness regarding the currently available hi-tech respiratory devices. In addition, an upsurge in the prevalence of respiratory conditions among both the pediatric and elderly populations will boost the market growth over the forecast years.

For instance, in September 2020, Teva Pharmaceuticals launched the AirDuo Digihare and ArmonAir Digihaler inhalation powder, two digital maintenance inhalers for patients with asthma.

COVID-19 Impact Analysis

COVID-19 had a substantial impact on the global digital dose inhalers market importantly on asthma for instance, according to the article titled "Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a National Incident Cohort Study" published in January 2022 adults with asthma were found to be at an increased risk of COVID-19 hospital admission compared with those without asthma conditions. Thus, increasing cases of COVID-19 are raising the cases of respiratory disorders which generates the need for digital dose inhalers.

Competitive Landscape

The major global players in the digital dose inhalers market include: Novartis International AG, Propeller Health, H&T Presspart Manufacturing Ltd, AptarGroup Inc, Amiko Digital Health Limited, Trudell Medical UK Limited, ReciPharm, Sensirion, Teva Pharmaceuticals, Cohero Health, Inc and among others.

Key Developments

  • In February 2022, AstraZeneca and Honeywell partnered to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less global warming potential than propellants currently used in respiratory medicines.
  • In October 2020, Zydus launched a pressurised Metered Dose Inhaler for COPD patient.

Why Purchase the Report?

  • To visualize the global digital dose inhalers market segmentation-based device type, application, type, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of digital dose inhalers market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global digital dose inhalers market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Device Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Type
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. Rise in the prevalence of respiratory diseases
      • 4.1.1.2. Rise in the technology advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Security issues
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Device Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 7.1.2. Market Attractiveness Index, By Device Type
  • 7.2. Metered Dose Inhalers *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Dry Powder Inhalers

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Asthma *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. COPD
  • 8.4. Others

9. By Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.1.2. Market Attractiveness Index, By Type
  • 9.2. Branded *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Generic

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Novartis International AG
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Propeller Health
  • 13.3. H&T Presspart Manufacturing Ltd
  • 13.4. AptarGroup Inc
  • 13.5. Amiko Digital Health Limited
  • 13.6. Trudell Medical UK Limited
  • 13.7. ReciPharm
  • 13.8. Sensirion
  • 13.9. Teva Pharmaceuticals
  • 13.10. Cohero Health, Inc

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us